APO-DECIDE

Apoptosis Modelling for Treatment Decisions in Colorectal Cancer

Coordinatore	ROYAL COLLEGE OF SURGEONS IN IRELAND    more  Organization address address: Saint Stephen's Green 123 city: DUBLIN postcode: 2 contact info Titolo: Prof. Nome: Jochen Cognome: Prehn Email: send email Telefono: 35314022261 Fax: 35314022447
Nazionalità Coordinatore	Ireland [IE]
Sito del progetto	http://www.apodecide.eu/
Totale costo	3˙896˙336 €
EC contributo	2˙999˙482 €
Programma	FP7-HEALTH Specific Programme "Cooperation": Health
Code Call	FP7-HEALTH-2012-INNOVATION-1
Funding Scheme	CP-FP
Anno di inizio	2012
Periodo (anno-mese-giorno)	2012-11-01   -   2014-10-31

 Partecipanti

#	participant	country	role	EC contrib. [€]
1	ROYAL COLLEGE OF SURGEONS IN IRELAND  Organization address address: Saint Stephen's Green 123 city: DUBLIN postcode: 2 contact info Titolo: Prof. Nome: Jochen Cognome: Prehn Email: send email Telefono: 35314022261 Fax: 35314022447	IE (DUBLIN)	coordinator	932˙803.80
2	OncoMark Limited  Organization address address: Weston Park 76 city: DUBLIN 14 postcode: - contact info Titolo: Ms. Nome: Mairin Cognome: Rafferty Email: send email Telefono: +353 1 7163666 Fax: +353 1 716 3709	IE (DUBLIN 14)	participant	508˙000.00
3	OPTIMATA LTD  Organization address address: ABBA HILLEL STREET 7 city: RAMAT GAN postcode: 52522 contact info Titolo: Dr. Nome: Marina Cognome: Kleiman Email: send email Telefono: 97237519226	IL (RAMAT GAN)	participant	461˙160.00
4	UNIVERSITE PARIS DESCARTES  Organization address address: Rue de l'Ecole de Medecine 12 city: PARIS postcode: 75270 contact info Titolo: Dr. Nome: Adeline Cognome: Lassaux Email: send email Telefono: 33176531748	FR (PARIS)	participant	362˙400.00
5	QUEEN'S UNIVERSITY BELFAST  Organization address address: University Road city: BELFAST postcode: BT7 1NN contact info Titolo: Mrs. Nome: Colleen Cognome: Spence Email: send email Telefono: +4428 9097 5183 Fax: +4428 9097 5182	UK (BELFAST)	participant	353˙442.00
6	KLINIKUM DER JOHANN WOLFGANG VON GOETHE UNIVERSITAET  Organization address address: Theodor Stern Kai 7 city: FRANKFURT AM MAIN postcode: 60590 contact info Titolo: Prof. Nome: Simone Cognome: Fulda Email: send email Telefono: +49 69 6786 6557 Fax: +49 69 6786 65 9157	DE (FRANKFURT AM MAIN)	participant	316˙876.20
7	PINTAIL LTD  Organization address address: SPRINGHILL AVENUE 77 city: BLACKROCK contact info Titolo: Mr. Nome: Ciaran Cognome: Clissmann Email: send email Telefono: +353 1 2899529	IE (BLACKROCK)	participant	64˙800.00

Mappa

 Word cloud

Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.

 Obiettivo del progetto (Objective)

'With the arrival of new colorectal cancer (CRC) therapeutics targeting specific cell signalling pathways, such as anti-EGFR therapy, personalised cancer treatment is at the door step of clinical practise. This progress in drug development contrasts strikingly with current clinical practice, where decision making depends largely on clinical factors such as tumour staging and age of patient, with the success of such treatments being largely unpredictable. 5-FU-based chemotherapy represents the main stay of CRC therapy. DNA damaging agents such as 5-FU and anti-EGFR therapy seek to induce tumour regression through induction of apoptosis or sensitization to apoptosis. Dysfunctional apoptosis is well recognized as a key contributing factor in chemotherapy resistance. The aim of the APODECIDE consortium is to develop systems medicine tools that predict treatment responses in CRC patients to 5-FU-based chemotherapy and anti-EGFR therapy, based on a systems analysis of apoptosis and EGFR signalling pathways. Based on previous clinical proof-of-concept studies that demonstrated the unique potential of such approaches in predicting tumour resistance, the APO-DECIDE consortium aims to deliver new clinical decision making tools that enable personalised medicine approaches and ‘smart’ clinical trials design in the future. The SMEs will benefit from the project through the development of systems-based combinatorial biomarkers adapted to formalin fixed paraffin-embedded material, the routine material used in clinical histopathology, hence providing a unique opportunity for marketing and exploitation. SMEs and their academic partners will also develop computational whole body models reflecting drug pharmacodynamics and pharmacokinetics in patient cohorts, providing a unique market niche in the field clinical oncology.'